← Leaderboards
Henry H. Balfour
University Of Minnesota Twin Cities
$14,130,793
Attributed
$14,130,793
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2005–13$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$14,130,793 · 9
By mechanism
U01$13,362,642 · 1
P01$715,370 · 1
M01$52,781 · 7
Top collaborators
No co-investigators on record.
Most similar at University Of Minnesota Twin Cities
Same institution · by research overlap
- David A. Zarkower$12,611,369
- Malgorzata Marjanska$3,451,255
- Stella Margaret Davies$7,181,470
- Marc K. Jenkins$34,351,766
- David Andrew Largaespada$17,551,730
Others in their field
Top investigators on “Protease Inhibitor”
- Constance Ann Benson · University Of California, San Diego$150,461,206
- Robert Turner Schooley · University Of Colorado Denver$48,400,257
- John Damon Chodera · Sloan-Kettering Inst Can Research$40,777,114
- Daniel R Kuritzkes · Brigham And Women'S Hospital$26,572,064
- David Heimbrook · Leidos Biomedical Research, Inc.$26,054,235
- Celia A. Schiffer · Univ Of Massachusetts Med Sch Worcester$24,364,826
Research focus
Protease InhibitorClinical ResearchAids TherapyHuman SubjectPharmacokineticsHuman Therapy EvaluationDrug InteractionsClinical Trial Phase IAidsGlucose MetabolismCytomegalovirusLipid MetabolismAids /Hiv NeuropathyStatistics /BiometryPneumocystis PneumoniaDrug Adverse EffectNucleoside AnalogPathologic ProcessAids Related Neoplasm /CancerHiv InfectionsHepatitis B Virus GroupExperimental DesignsAntiaids AgentBody Composition
Grant awards (30)
Viral Infections and Posttransplant Morbidity$130,835
P01 · FY2013 · DK · contact PI
Viral Infections and Posttransplant Morbidity$137,740
P01 · FY2012 · DK · contact PI
Viral Infections and Posttransplant Morbidity$139,964
P01 · FY2011 · DK · contact PI
Viral Infections and Posttransplant Morbidity$143,731
P01 · FY2010 · DK · contact PI
Viral Infections and Posttransplant Morbidity$163,100
P01 · FY2009 · DK · contact PI
ADULT AIDS CLINICAL TRIALS UNIT$742,256
U01 · FY2008 · AI · contact PI
A5229A PHASE II/III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF URIDI$1,325
M01 · FY2008 · RR · contact PI
ADULT AIDS CLINICAL TRIALS UNIT$1,182,738
U01 · FY2007 · AI · contact PI
ACTG A5142: A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON OF LOPINAVIR/RITONAVI$3,316
M01 · FY2007 · RR · contact PI
ACTG A5163: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ON$2,212
M01 · FY2007 · RR · contact PI
A5229A PHASE II/III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF URIDI$1,104
M01 · FY2007 · RR · contact PI
ADULT AIDS CLINICAL TRIALS UNIT$1,730,607
U01 · FY2006 · AI · contact PI
ADULT AIDS CLINICAL TRIALS UNIT$1,744,996
U01 · FY2005 · AI
ADULT AIDS CLINICAL TRIALS UNIT$1,534,166
U01 · FY2004 · AI
ADULT AIDS CLINICAL TRIALS UNIT$37,098
U01 · FY2004 · AI
ADULT AIDS CLINICAL TRIALS UNIT$1,757,447
U01 · FY2003 · AI
ADULT AIDS CLINICAL TRIALS UNIT$1,564,044
U01 · FY2002 · AI
ACTG 384 PROTEASE INHIBITOR, NN REVERSE TRANSCRIPTASE INHIBITOR, DUAL NUCLEOSIDE$0
M01 · FY2002 · RR
ACTG 384 PROTEASE INHIBITOR, NN REVERSE TRANSCRIPTASE INHIBITOR, DUAL NUCLEOSIDE$0
M01 · FY2002 · RR
PK INTERACTIONS: PROTEASE INHIBITORS /LIPID LOWERING$0
M01 · FY2002 · RR
PK INTERACTIONS: PROTEASE INHIBITORS /LIPID LOWERING$0
M01 · FY2002 · RR
ADULT AIDS CLINICAL TRIALS UNIT$1,485,507
U01 · FY2001 · AI
ADULT AIDS CLINICAL TRIALS UNIT$65,000
U01 · FY2001 · AI
ADULT AIDS CLINICAL TRIALS UNIT$55,722
U01 · FY2001 · AI
PK INTERACTIONS: PROTEASE INHIBITORS /LIPID LOWERING$0
M01 · FY2001 · RR
ACTG 384 PROTEASE INHIBITOR, NN REVERSE TRANSCRIPTASE INHIBITOR, DUAL NUCLEOSIDE$0
M01 · FY2001 · RR
ADULT AIDS CLINICAL TRIALS UNIT$1,463,061
U01 · FY2000 · AI
A PHASE I STUDY OF THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF THALIDOMIDE$44,824
M01 · FY2000 · RR
PK INTERACTIONS: PROTEASE INHIBITORS /LIPID LOWERING$0
M01 · FY2000 · RR
ACTG 384 PROTEASE INHIBITOR, NN REVERSE TRANSCRIPTASE INHIBITOR, DUAL NUCLEOSIDE$0
M01 · FY2000 · RR